Clinical bottom line
Pediatric sudden-onset sensorineural hearing loss (SSNHL) with genetic etiologies represents a distinct and increasingly recognized subset of acute hearing loss in children. Advances in genetic testing have improved diagnostic precision, revealing underlying hereditary causes that may influence prognosis and management. Current evidence supports integrating genetic evaluation alongside standard audiologic and imaging assessments to guide individualized treatment strategies. However, clinical guidelines remain evolving, and the role of targeted therapies based on genetic findings is still largely investigational. Clinicians should maintain a high index of suspicion for genetic contributions in pediatric SSNHL cases, particularly when family history or syndromic features are present.
What the evidence shows
Sudden sensorineural hearing loss in children is rare but clinically significant, with etiologies spanning viral, vascular, autoimmune, and genetic causes (Hanson et al., 2026; Lambert et al., 2018). Recent literature highlights that genetic factors may underlie a meaningful proportion of pediatric SSNHL cases, often missed in earlier diagnostic paradigms focused primarily on acquired causes (Hanson et al., 2026). Advances in next-generation sequencing and gene panels have enabled identification of mutations in genes associated with hereditary hearing loss syndromes, such as GJB2, SLC26A4, and mitochondrial DNA variants, which may present with sudden or rapidly progressive hearing loss (Hanson et al., 2026).
MRI remains a critical complementary diagnostic tool to exclude retrocochlear pathology and to assess inner ear structures, but it does not detect genetic abnormalities (Herrera et al., 2024). Genetic testing is increasingly recommended as part of the diagnostic workup, especially in cases with bilateral involvement, recurrent episodes, or a positive family history (Rodríguez Izquierdo et al., 2024; Hanson et al., 2026). Practice trends indicate variability in the uptake of genetic testing in pediatric SSNHL, reflecting ongoing uncertainty about its clinical utility and cost-effectiveness (Luu et al., 2023).
Therapeutic approaches for pediatric SSNHL with genetic etiologies remain largely extrapolated from adult protocols and non-genetic cases. Corticosteroids are the mainstay of treatment, although response rates may differ depending on the underlying genetic mutation (Lambert et al., 2018). Emerging adjunctive therapies, including hyperbaric oxygen therapy, have shown promise in improving outcomes but require further validation in genetically defined pediatric cohorts (Shaheen et al., 2024). Early identification of genetic causes may facilitate counseling, prognostication, and consideration of cochlear implantation or gene therapy trials in refractory cases (Hanson et al., 2026).
Caveats and uncertainty
The evidence base for genetic contributions to pediatric SSNHL is still developing, with many studies limited by small sample sizes and heterogeneous populations (Hanson et al., 2026). The penetrance and expressivity of identified mutations vary widely, complicating interpretation of genetic test results and their implications for treatment. There is no consensus yet on standardized genetic testing panels or algorithms specific to pediatric SSNHL (Luu et al., 2023).
Moreover, the natural history and treatment responsiveness of genetically mediated SSNHL may differ from idiopathic or acquired forms, but robust comparative data are lacking. The impact of genetic findings on long-term hearing outcomes and quality of life remains uncertain. Additionally, access to genetic testing and counseling services is variable across healthcare settings, potentially limiting equitable implementation (Rodríguez Izquierdo et al., 2024).
Finally, while hyperbaric oxygen therapy and other novel interventions show potential, high-quality randomized controlled trials in pediatric populations with confirmed genetic etiologies are absent, warranting cautious interpretation (Shaheen et al., 2024).
How this may change practice
Clinicians managing pediatric SSNHL should consider incorporating genetic evaluation into the diagnostic pathway, particularly for patients with bilateral hearing loss, recurrent episodes, or suggestive family history. Early genetic diagnosis may refine prognostic counseling and influence decisions regarding monitoring intensity and therapeutic interventions.
Multidisciplinary collaboration involving otolaryngologists, audiologists, geneticists, and genetic counselors is essential to optimize care and interpret complex genetic results. Awareness of emerging adjunctive therapies such as hyperbaric oxygen therapy may expand treatment options, though these should be applied judiciously pending further evidence.
Ultimately, integrating genetic insights into clinical practice represents a step toward precision medicine in pediatric SSNHL, enabling tailored management strategies that may improve outcomes and inform future research directions.